Nothing Special   »   [go: up one dir, main page]

SE0101932D0 - Pharmaceutical combinations - Google Patents

Pharmaceutical combinations

Info

Publication number
SE0101932D0
SE0101932D0 SE0101932A SE0101932A SE0101932D0 SE 0101932 D0 SE0101932 D0 SE 0101932D0 SE 0101932 A SE0101932 A SE 0101932A SE 0101932 A SE0101932 A SE 0101932A SE 0101932 D0 SE0101932 D0 SE 0101932D0
Authority
SE
Sweden
Prior art keywords
pharmaceutical combinations
formula
pharmaceutically acceptable
acceptable derivative
combinations
Prior art date
Application number
SE0101932A
Other languages
English (en)
Inventor
John Dixon
Robert Humphries
Alexander Nicol
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0101932A priority Critical patent/SE0101932D0/sv
Publication of SE0101932D0 publication Critical patent/SE0101932D0/sv
Priority to TW091110514A priority patent/TWI232751B/zh
Priority to ARP020101955A priority patent/AR034343A1/es
Priority to AU2002305952A priority patent/AU2002305952B2/en
Priority to PCT/SE2002/001033 priority patent/WO2002096428A1/en
Priority to PL02366510A priority patent/PL366510A1/xx
Priority to CZ20033246A priority patent/CZ20033246A3/cs
Priority to EP02733751A priority patent/EP1397139A1/en
Priority to HU0400069A priority patent/HUP0400069A3/hu
Priority to JP2002592938A priority patent/JP2004532869A/ja
Priority to CNB028109120A priority patent/CN100352442C/zh
Priority to BR0210034-7A priority patent/BR0210034A/pt
Priority to MXPA03010761A priority patent/MXPA03010761A/es
Priority to SK1473-2003A priority patent/SK14732003A3/sk
Priority to EEP200300589A priority patent/EE200300589A/xx
Priority to CA002447648A priority patent/CA2447648A1/en
Priority to IL15878002A priority patent/IL158780A0/xx
Priority to RU2003133216/15A priority patent/RU2331422C2/ru
Priority to US10/479,019 priority patent/US20040146498A1/en
Priority to KR10-2003-7015565A priority patent/KR20040003029A/ko
Priority to ZA200308780A priority patent/ZA200308780B/en
Priority to IS7051A priority patent/IS7051A/is
Priority to NO20035315A priority patent/NO20035315D0/no
Priority to CO03105239A priority patent/CO5550445A2/es
Priority to US11/406,746 priority patent/US20060189584A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE0101932A 2001-05-31 2001-05-31 Pharmaceutical combinations SE0101932D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations
TW091110514A TWI232751B (en) 2001-05-31 2002-05-20 Pharmaceutical combinations
ARP020101955A AR034343A1 (es) 2001-05-31 2002-05-24 Combinaciones farmaceuticas
KR10-2003-7015565A KR20040003029A (ko) 2001-05-31 2002-05-29 약학 조합물
CNB028109120A CN100352442C (zh) 2001-05-31 2002-05-29 药物组合
EEP200300589A EE200300589A (et) 2001-05-31 2002-05-29 Ravimkoostised
PL02366510A PL366510A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
CZ20033246A CZ20033246A3 (cs) 2001-05-31 2002-05-29 Farmaceutická kompozice obsahující antagonistu receptoru P2T a další antitrombotické činidlo a její použití při léčení trombózy
EP02733751A EP1397139A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
HU0400069A HUP0400069A3 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations and their use in preventing and treating the thrombosis
JP2002592938A JP2004532869A (ja) 2001-05-31 2002-05-29 医薬組成物
AU2002305952A AU2002305952B2 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
BR0210034-7A BR0210034A (pt) 2001-05-31 2002-05-29 Conjunto de partes, método para tratamento de trombose, uso de um composto, formulação farmacêutica, uso e processo para preparação da mesma, e, composto
MXPA03010761A MXPA03010761A (es) 2001-05-31 2002-05-29 Combinaciones farmaceuticas.
SK1473-2003A SK14732003A3 (sk) 2001-05-31 2002-05-29 Farmaceutická kompozícia obsahujúca antagonistu receptora P2T a ďalšie antitrombotické činidlo a jej použitie pri liečení trombózy
PCT/SE2002/001033 WO2002096428A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
CA002447648A CA2447648A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
IL15878002A IL158780A0 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations comprising a p2t (p2y12) receptor antagonist and another anti-thrombotic agent and their use in the treatment and prevention of thrombosis
RU2003133216/15A RU2331422C2 (ru) 2001-05-31 2002-05-29 Фармацевтические комбинации
US10/479,019 US20040146498A1 (en) 2001-05-31 2002-05-29 Pharmaceutical combinations
ZA200308780A ZA200308780B (en) 2001-05-31 2003-11-11 Pharmaceutical combinations.
IS7051A IS7051A (is) 2001-05-31 2003-11-26 Lyfjasamsetningar
NO20035315A NO20035315D0 (no) 2001-05-31 2003-11-28 Farmasöytiske kombinasjoner
CO03105239A CO5550445A2 (es) 2001-05-31 2003-11-28 Combinaciones farmaceuticas
US11/406,746 US20060189584A1 (en) 2001-05-31 2006-04-17 Pharmaceutical combinations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
SE0101932D0 true SE0101932D0 (sv) 2001-05-31

Family

ID=20284321

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0101932A SE0101932D0 (sv) 2001-05-31 2001-05-31 Pharmaceutical combinations

Country Status (24)

Country Link
US (2) US20040146498A1 (sv)
EP (1) EP1397139A1 (sv)
JP (1) JP2004532869A (sv)
KR (1) KR20040003029A (sv)
CN (1) CN100352442C (sv)
AR (1) AR034343A1 (sv)
AU (1) AU2002305952B2 (sv)
BR (1) BR0210034A (sv)
CA (1) CA2447648A1 (sv)
CO (1) CO5550445A2 (sv)
CZ (1) CZ20033246A3 (sv)
EE (1) EE200300589A (sv)
HU (1) HUP0400069A3 (sv)
IL (1) IL158780A0 (sv)
IS (1) IS7051A (sv)
MX (1) MXPA03010761A (sv)
NO (1) NO20035315D0 (sv)
PL (1) PL366510A1 (sv)
RU (1) RU2331422C2 (sv)
SE (1) SE0101932D0 (sv)
SK (1) SK14732003A3 (sv)
TW (1) TWI232751B (sv)
WO (1) WO2002096428A1 (sv)
ZA (1) ZA200308780B (sv)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867199B2 (en) 2000-08-21 2005-03-15 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapeutic use
JP2004346067A (ja) * 2003-04-28 2004-12-09 Mitsubishi Pharma Corp 抗血栓薬の治療可能時間を延長するための薬剤
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7749980B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Non-nucleotide compositions and method for treating pain
US20090075949A1 (en) * 2004-10-25 2009-03-19 Wolfgang Eisert Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
US9532945B2 (en) * 2006-04-04 2017-01-03 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor
CA2668180A1 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as adp p2y12 receptor antagonists
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
US20130045192A1 (en) * 2009-11-09 2013-02-21 Alexion Pharmaceuticals, Inc. Reagents and methods for detecting pnh type ii white blood cells and their identification as risk factors for thrombotic disorders
WO2011067571A1 (en) * 2009-12-03 2011-06-09 Astrazeneca Ab Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor
WO2011076401A1 (de) 2009-12-23 2011-06-30 Holger Schankin Acetylsalicylsäure-haltige, im wesentlichen wasserfreie pharmazeutische zusammensetzungen
US8663661B2 (en) 2009-12-23 2014-03-04 Ratiopharm Gmbh Solid pharmaceutical dosage form of ticagrelor
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
US9101642B2 (en) * 2011-06-01 2015-08-11 Astrazeneca Ab Ticagrelor co-crystal
CN105377240A (zh) * 2013-05-29 2016-03-02 拉蒂奥法姆有限责任公司 固体药物剂型
CN104277039B (zh) * 2014-09-19 2016-06-01 广东东阳光药业有限公司 含有取代丁炔基的吡唑并哌啶酮类化合物及其组合物及用途
WO2016116942A1 (en) * 2015-01-20 2016-07-28 Anlon Chemical Research Organization Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin
AU2016210973B2 (en) * 2015-01-27 2019-02-14 Astrazeneca Ab Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
CN106204544B (zh) * 2016-06-29 2019-04-05 南京中观软件技术有限公司 一种自动提取图像中标志点位置及轮廓的方法和系统

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9404196D0 (sv) * 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
SK283206B6 (sk) * 1995-07-11 2003-03-04 Astra Pharmaceuticals Ltd. Inhibítory agregácie krvných doštičiek, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
BR0010381A (pt) * 1999-03-11 2002-02-05 Du Pont Pharm Co Método de tratamento da trombose em um mamìfero, e uso de uma combinação de (i) um inibidor do fator xa, e (ii) um composto selecionado do grupo que consiste em aspirina, tpa, um antagonista gpiib/iiia, heparina de baixo peso molecular e heparina
AR023510A1 (es) * 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations

Also Published As

Publication number Publication date
US20060189584A1 (en) 2006-08-24
MXPA03010761A (es) 2004-03-02
WO2002096428A1 (en) 2002-12-05
US20040146498A1 (en) 2004-07-29
EP1397139A1 (en) 2004-03-17
SK14732003A3 (sk) 2004-05-04
IS7051A (is) 2003-11-26
JP2004532869A (ja) 2004-10-28
ZA200308780B (en) 2005-02-11
EE200300589A (et) 2004-02-16
CO5550445A2 (es) 2005-08-31
HUP0400069A2 (hu) 2004-04-28
KR20040003029A (ko) 2004-01-07
AR034343A1 (es) 2004-02-18
TWI232751B (en) 2005-05-21
CN1512885A (zh) 2004-07-14
AU2002305952B2 (en) 2007-08-09
RU2331422C2 (ru) 2008-08-20
RU2003133216A (ru) 2005-04-20
BR0210034A (pt) 2004-08-10
NO20035315D0 (no) 2003-11-28
CZ20033246A3 (cs) 2004-02-18
IL158780A0 (en) 2004-05-12
CA2447648A1 (en) 2002-12-05
PL366510A1 (en) 2005-02-07
HUP0400069A3 (en) 2006-02-28
CN100352442C (zh) 2007-12-05

Similar Documents

Publication Publication Date Title
SE0101932D0 (sv) Pharmaceutical combinations
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
BG108269A (en) Pyrazolopyrimidines as therapeutic agents
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
DE60112974D1 (en) Carbolinderivate
DE602004024375D1 (de) Carboxamidderivate
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DE60216233D1 (en) Carbolinderivate
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
DE60121461D1 (de) Kondensierte pyridoindolderivate
ATE303384T1 (de) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
WO2002070469A3 (en) Selective pde3b inhibitors and use of the same in therapy
SE0102440D0 (sv) New compound
SE0102716D0 (sv) Novel compounds
DK1379508T3 (da) N-(aryl)-2arylethensulfonamider og terapeutiske anvendelser deraf
DE60112960D1 (de) Kondensierte pyridoindolderivate
SE0003476D0 (sv) Compounds
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
MXPA04005809A (es) Inhibidores de proteinas quinasas.
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents